Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen in prostate cancer.

M Kuriyama1

  • 1Department of Urology, Gifu University School of Medicine, Japan.

The International Journal of Biological Markers
|May 1, 1986
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2016
Same author

Letter: deleterious effects of smoking on post-operative Crohn's disease.

Alimentary pharmacology & therapeutics·2016
Same author

A metagenetic approach for revealing community structure of marine planktonic copepods.

Molecular ecology resources·2014
Same author

Hashimoto encephalopathy presenting with progressive cerebellar ataxia.

BMJ case reports·2011
Same author

Successful treatment of wound breakdown caused by pyoderma gangrenosum after total knee arthroplasty.

The Knee·2010
Same author

Acute on chronic subdural hematoma as a rare complication in a microscopic polyangiitis patient receiving antithrombotic treatment.

Clinical nephrology·2009
Same journal

The diagnostic and predictive value of miR-145-3p in gastric cancer and its regulation of gastric cancer progression via targeting CREB1.

The International journal of biological markers·2026
Same journal

PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer.

The International journal of biological markers·2026
Same journal

Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze-thaw stability.

The International journal of biological markers·2026
Same journal

Expression of concern: "RIPK4 is Downregulated in Poorly Differentiated Tongue Cancer and is Associated with Migration/Invasion and Cisplatin-Induced Apoptosis".

The International journal of biological markers·2026
Same journal

Association of NF-kappaBIA rs696 gene polymorphism with breast cancer risk in Bangladeshi women: A case-control study.

The International journal of biological markers·2026
Same journal

Circulating tumor cells and tumor-derived cell-free DNA in cancer management: Clinical evidence, limitations, and future directions.

The International journal of biological markers·2026
See all related articles

Prostate-specific antigen (PSA) shows promise as a tumor marker for prostate cancer detection. While effective, it presents a high false positive rate in benign prostatic hypertrophy cases, necessitating further evaluation.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Prostate-specific antigen (PSA) is a clinically evaluated tumor marker for prostate cancer.
  • Enzyme immunoassay (EIA) is a common method for PSA detection.

Purpose of the Study:

  • To evaluate the utility of serum PSA as a tumor marker for prostate cancer detection.
  • To assess the diagnostic performance of PSA in different populations and conditions.

Main Methods:

  • Assayed serum PSA levels in 1,109 individuals using EIA.
  • Established upper cut-off values for PSA based on normal controls (Americans: 2.5 ng/ml, Japanese: 1.2 ng/ml).
  • Compared PSA levels in prostate cancer patients and those with benign prostatic hypertrophy (BPH).

Main Results:

Related Experiment Videos

  • Serum PSA was positive in 78% of American and 62% of Japanese prostate cancer patients.
  • A high false positive rate of 41% was observed in American BPH cases.
  • Simultaneous assays of PSA and prostatic acid phosphatase (PAP) demonstrated high sensitivity and specificity.

Conclusions:

  • PSA is a potentially useful tumor marker for prostate cancer detection and monitoring.
  • Combined PSA and PAP assays enhance diagnostic accuracy.
  • Pre-treatment serum PSA levels may indicate cancer's malignant potential.